Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Price to Sales Ratio (P/S) on January 14, 2025: 9.08

Supriya Lifescience Limited Price to Sales Ratio (P/S) is 9.08 on January 14, 2025, a 69.07% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Supriya Lifescience Limited 52-week high Price to Sales Ratio (P/S) is 11.26 on November 22, 2024, which is 23.90% above the current Price to Sales Ratio (P/S).
Supriya Lifescience Limited 52-week low Price to Sales Ratio (P/S) is 4.72 on June 04, 2024, which is -48.01% below the current Price to Sales Ratio (P/S).
Supriya Lifescience Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 7.01.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years